STOCK TITAN

CME Group (CME) director awarded 645 fully vested Class A shares

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Lucas Deborah J reported acquisition or exercise transactions in this Form 4 filing.

CME Group Inc. director Deborah J. Lucas received an equity award of Class A common stock. She was granted 645 fully vested shares at a price of $225 per share as part of CME Group’s annual equity compensation program for non-employee directors under the CME Group Director Stock Plan. Following this grant, she directly holds 4,533 Class A shares. This is a compensation-related stock award, not an open-market purchase.

Positive

  • None.

Negative

  • None.
Insider Lucas Deborah J
Role null
Type Security Shares Price Value
Grant/Award Common Stock Class A 645 $225.00 $145K
Holdings After Transaction: Common Stock Class A — 4,533 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Shares granted 645 shares Class A Common Stock grant to director
Grant price $225 per share Reported value for granted shares
Post-transaction holdings 4,533 shares Direct Class A holdings after grant
fully vested financial
"Represents a grant of fully vested shares of Class A Common Stock"
annual equity compensation program financial
"issued to the Reporting Person as part of the Issuer's annual equity compensation program"
non-employee directors financial
"equity compensation program for non-employee directors under the CME Group Director Stock Plan"
Non-employee directors are board members who do not work for the company as salaried employees and usually do not hold day-to-day management roles. They act like outside referees or independent coaches, providing oversight, asking tough questions, and protecting shareholders’ interests; investors care because these directors help ensure management is accountable, reduce conflicts of interest, and influence decisions that affect company strategy and long-term value.
CME Group Director Stock Plan financial
"for non-employee directors under the CME Group Director Stock Plan"
Form 4 regulatory
"INSIDER FILING DATA (Form 4):"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lucas Deborah J

(Last)(First)(Middle)
20 S. WACKER DRIVE

(Street)
CHICAGO ILLINOIS 60606

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
CME GROUP INC. [ CME ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock Class A06/25/2026A(1)645A$2254,533D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents a grant of fully vested shares of Class A Common Stock issued to the Reporting Person as part of the Issuer's annual equity compensation program for non-employee directors under the CME Group Director Stock Plan. These shares are not subject to any vesting conditions.
Remarks:
/s/ Elizabeth Hensen, as Attorney-in-Fact for Deborah J. Lucas06/29/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did CME (CME) director Deborah J. Lucas report?

Deborah J. Lucas reported receiving a grant of 645 fully vested CME Group Class A common shares at $225 per share as part of the company’s annual equity compensation program for non-employee directors.

Was the CME (CME) Lucas transaction a market purchase or a stock grant?

The transaction was a stock grant, not a market purchase. Lucas received 645 fully vested Class A shares as compensation under the CME Group Director Stock Plan for non-employee directors.

How many CME Group (CME) shares does Deborah J. Lucas own after this Form 4?

After the reported grant, Deborah J. Lucas directly owns 4,533 shares of CME Group Class A common stock, reflecting her updated direct equity stake as a non-employee director.

Are the CME (CME) shares granted to Deborah J. Lucas subject to vesting?

The 645 shares granted to Deborah J. Lucas are fully vested. The filing notes these Class A shares are not subject to any vesting conditions under the CME Group Director Stock Plan.

At what price were the CME (CME) shares granted to Deborah J. Lucas valued?

The grant to Deborah J. Lucas was reported at $225 per share for 645 Class A common shares, indicating the per-share value used for this equity compensation award to the non-employee director.